See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
HighCape Capital is a growth equity fund created in 2013 focused exclusively on Life Sciences — specifically Connected Health, Medical Device/Tool, and Biotechnology. The firm targets innovative companies in the early revenue or product launch stage that have a superior product delivering clear value to the healthcare system and a defined path to commercialization, with a target portfolio of 6–8 companies per fund. HighCape takes a hands-on, collaborative approach: its multidisciplinary team of industry veterans with 25+ years of experience each works directly alongside management teams to augment commercial and operational strategies, 'jump in' to expand talent when necessary, and drive portfolio companies toward sustainable businesses with multiple exit alternatives.
Notable quotes
“We are committed to developing a focused and specialized portfolio because we expect to play an active role in shaping each portfolio company's commercial strategy. We excel when we have the opportunity to assist management teams in executing on an agreed upon path to growth.”
“Many companies have difficulty transitioning from the product development stage to the commercialization stage and we believe HighCape Partners is uniquely positioned to leverage our collective experience to truly add value to our portfolio companies, thereby achieving a higher probability of success.”
“There is a great unmet need for precision medicine approaches that are specifically focused on cancer metabolism, and Athena will fill this gap. This initial investment will allow the Company to expand its footprint and efforts in Connecticut with the goal of building a robust precision medicine company.”
Team
Matt Zuga
Co-Founder & Partner
Dean Tozer
Partner
Jennifer Barretta
Partner
Charles Hart, PhD
Operating Partner
Ranjit Bindra, MD, PhD
Operating Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Modifi Biosciences | Seed | $4m | 2023-10-17 |
| Elutia | Growth | — | — |
| Quantum-Si | SPAC/Public | — | 2021-06-01 |
| Wellinks | Series C | $25m | 2021-11-01 |
| Cybrexa Therapeutics | Series B | $13m | 2019-06-20 |
| Alphina Therapeutics | Seed | — | — |
| TELA Bio | Growth | — | — |
| Cheetah Medical | Series C | $12m | 2017-09-12 |
| Zipline Medical | Other Equity | $9m | 2018-06-19 |
| Aziyo Biologics | Post-IPO | — | 2021-12-08 |
Frequent co-investors
Fit check
Is HighCape Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit